New drug shows promise against tough breast cancers
NCT ID NCT04243616
First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 24 times
Summary
This study tests whether the drug cemiplimab can help shrink or eliminate breast cancer before surgery in people with high-risk or locally advanced luminal or triple-negative breast cancer. 36 participants will receive the drug and then have their tumor tissue checked for a complete response. The goal is to see if this immunotherapy can improve outcomes for these aggressive cancer types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Froedtert Hospital & Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Conditions
Explore the condition pages connected to this study.